Resource library

The Australian Group on Antimicrobial Resistance (AGAR) monitors AMR, epidemiologic and genetic patterns in bloodstream infections in Australia relating to three main organisms: Staphylococcus aureus, enterococcal species and gram-negative organisms. The 2020 AGAR Sepsis Outcome Programs Report provides analyses of data on AMR associated with episodes of bacteraemia, reported by 30 laboratories servicing 49 public and private institutions across Australia in 2020.

Update 25 provides data submitted to CARAlert for the reporting period 1 September to 31 October 2021 to support prevention and containment of antimicrobial resistance.

Update 24 provides data submitted to CARAlert for the reporting period 1 July 2021 to 31 August 2021 to support prevention and containment of antimicrobial resistance.

Update 23 provides data submitted to CARAlert for the reporting period 1 May 2021 to 30 June 2021to support prevention and containment of antimicrobial resistance.

The Highlights Report provides an overview of the key messages of AURA 2021 and a summary of highlights from selected chapters. 

AURA 2021 is the fourth in a series of national reports on the critical issues of antimicrobial resistance (AMR), and the use of antimicrobials (AU), in Australia.

Chapter 6 brings together a range of topics, resulting from new areas of collaboration by the Commission AURA team to enhance the provision of resistance data. Chapter 6 also includes an update on international comparisons of AMR and AU. This resource provides figures and tables from Chapter 6 for use in presentations, and other documents, to allow ease of access to data for quality improvement. 

AURA 2021 is the fourth in a series of national reports on the critical issues of antimicrobial resistance (AMR), and the use of antimicrobials (AU), in Australia.

The focus of Chapter 5 is CARAlert, the National Alert System for Critical Antimicrobial Resistances in Australia; this resource providing figures and tables for use in presentations and other documents, to allow ease of access to data at the local and jurisdiction levels. 

AURA 2021 is the fourth in a series of national reports on the critical issues of antimicrobial resistance (AMR), and the use of antimicrobials (AU) in Australia. The focus of Chapter 4 is AMR in Australia, with this resource providing figures and tables for use in presentations and other documents, to allow ease of access to data at the local level, and for all jurisdictions. 

AURA 2021 is the fourth in a series of national reports on the critical issues of antimicrobial resistance (AMR), and the use of antimicrobials (AU), in Australia.

The focus of Chapter 3 is antimicrobial use and the appropriateness of use in Australia; this resource provides figures and tables for use in presentations and other documents, to allow ease of access to data at the local level, and for all jurisdictions. 

The Consumer Summary provides an overview of the key findings and messages of AURA 2021 for consumers.

This report provides supplementary data relevant to Chapter 4 of AURA 2021 - Antimicrobial resistance.

This report includes analyses of antimicrobial resistance and antimicrobial use data predominantly collected in 2018 and 2019, and 2020 data from the National Alert System for Critical Antimicrobial Resistances (CARAlert) the Pharmaceutical Benefits Scheme (PBS) in the context of the COVID-19 pandemic.

This latest CARAlert Data Update includes data submitted to CARAlert between 1 March 2021 and 30 April 2021. This update provides useful information to support prevention and containment of antimicrobial resistance.

Chapter 16 of the AMS Book highlights issues related to antimicrobial use in the community and in residential aged care and describes infections experienced by older people and strategies to improve antimicrobial prescribing and use. 

The CARAlert Annual Report for 2020 is now available.

This report provides an update on data submitted to CARAlert for the reporting period 1 January 2021 to 28 February 2021, and complements previous analyses and updates of CARAlert data, and the CARAlert 2020 Annual Report. The data update provides information to support prevention and containment of antimicrobial resistance.

The 2019 AGAR Sepsis Outcome Report is now available.

The 2019 Hospital NAPS report includes analyses of detailed information about prescribing practices in Australian public and private acute hospitals in 2019. The findings can be used to guide quality improvement programs and improve the safety of care for patients.

This graphic can be used for organisations to print on t-shirts if that is a local activity for Antimicrobial Awareness Week - courtesy of NPS MedicineWise.

This report documents changes in methicillin-resistant Staphylococcus aureus (MRSA) which occurred in Australia between 2000 to 2014. 

This report by the Sub-Committee on Best-Practice Pricing and Clinical Quality Information (the Sub-Committee) was endorsed by the Joint Working Party on Pricing for Safety and Quality in Australian Public Hospitals (JWP) of the Independent Health and Aged Care Pricing Authority (IHACPA) and the Australian Commission on Safety and Quality in Health Care (the Commission) on 29 June 2015.

Antimicrobial Use in Australian Hospitals

2016 report.

This survey aims to provide acute care facilities with a tool for evaluating staff perceptions of the rapid response system.